LEADER 03459nam 2200505 450 001 9910795596603321 005 20230316232537.0 010 $a0-309-46266-5 010 $a0-309-46264-9 035 $a(CKB)4340000000215693 035 $a(MiAaPQ)EBC5109491 035 $a(EXLCZ)994340000000215693 100 $a20171122h20172017 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 00$aEnabling precision medicine $ethe role of genetics in clinical drug development : proceedings of a workshop /$fMorgan L. Boname [and four others], rapporteurs 210 1$aWashington, District of Columbia :$cThe National Academies Press,$d2017. 210 4$dİ2017 215 $a1 online resource (122 pages) $cillustrations (some color) 311 $a0-309-46263-0 320 $aIncludes bibliographical references. 327 $aIntroduction -- Overarching considerations for implementing successful genetics-enabled drug development -- Case studies in precision drug development -- Integrating genetics into the drug development pathway for complex diseases -- Finding innovative ways to integrate genetic research into the drug development process -- Reflecting back and looking forward: key themes and potential next steps in genetics-enabled drug development -- Appendix A: References -- Appendix B: Statement of task and workshop agenda -- Appendix C: Speaker biographical sketches -- Appendix D: Registered attendees. 330 1 $a"Those involved in the drug development process face challenges of efficiency and overall sustainability due in part to high research costs, lengthy development timelines, and late-stage drug failures. Novel clinical trial designs that enroll participants based on their genetics represent a potentially disruptive change that could improve patient outcomes, reduce costs associated with drug development, and further realize the goals of precision medicine. On March 8, 2017, the Forum on Drug Discovery, Development, and Translation and the Roundtable on Genomics and Precision Health of the National Academies of Sciences, Engineering, and Medicine hosted the workshop Enabling Precision Medicine: The Role of Genetics in Clinical Drug Development. Participants examined successes, challenges, and possible best practices for effectively using genetic information in the design and implementation of clinical trials to support the development of precision medicines, including exploring the potential advantages and disadvantages of such trials across a variety of disease areas. This publication summarizes the presentations and discussions from the workshop"--Publisher's description. 606 $aDrug development$vCongresses 606 $aPrecision medicine$vCongresses 606 $aPharmacogenetics$vCongresses 615 0$aDrug development 615 0$aPrecision medicine 615 0$aPharmacogenetics 676 $a615.190072 702 $aBoname$b Morgan L. 712 02$aInstitute of Medicine (U.S.).$bForum on Drug Discovery, Development, and Translation. 712 02$aRoundtable on Genomics and Precision Health. 712 02$aBoard on Health Sciences Policy. 712 02$aHealth and Medicine Division. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910795596603321 996 $aEnabling precision medicine$93690635 997 $aUNINA